BMP4 promotes prostate tumor growth in bone through osteogenesis

Cancer Research

Volumn 71, Issue 15, 2011, Pages 5194-5203

  Lee, Yu Chen ^a   Cheng, Chien Jui ^c,d   Bilen, Mehmet A ^a   Lu, Jing Fang ^a   Satcher, Robert L ^a   Yu Lee, Li Yuan ^b   Gallick, Gary E ^a   Maity, Sankar N ^a   Lin, Sue Hwa ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 4; EOTAXIN 2; INTERLEUKIN 8; LDN 193189; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BONE DEVELOPMENT; BONE METASTASIS; CANCER GROWTH; CELL DIFFERENTIATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SCID MOUSE; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ANIMALS; AUTOCRINE COMMUNICATION; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE NEOPLASMS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; CYTOKINES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, SCID; NEOPLASM PROTEINS; OSSIFICATION, HETEROTOPIC; OSTEOBLASTS; OSTEOGENESIS; PROSTATIC NEOPLASMS; PYRAZOLES; PYRIMIDINES; RECOMBINANT PROTEINS; SUBCUTANEOUS TISSUE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960960617     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4374     Document Type: Article

References (22)

1. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983;21:337-44. (Pubitemid 13161851)
2. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16. (Pubitemid 39665537)
3. Saad F, Lipton A. Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Curr Opin Support Palliat Care 2010;4:127-34.
4. Logothetis C, Lin S-H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8. (Pubitemid 40052322)
5. Li Z, Mathew P, Yang J, Starbuck M-W, Zurita AJ, Liu J, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. J Clin Invest 2008;118:2697-710.
6. Rossert J, Eberspaecher H, de Crombrugghe B. Separate cis-acting DNA elements of the mouse pro-alpha 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J Cell Biol 1995;129:1421-32.
7. Zilberberg L, ten Dijke P, Sakai LY, Rifkin DB. A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biol 2007;8:41.
8. Marie PJ, Debiais F, Haÿ E. Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling. Histol Histopathol 2002;17:877-85. (Pubitemid 34784671)
9. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 2010;29:3196-207.
10. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 2002;277: 4883-91. (Pubitemid 34968524)
11. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med 2008;14:1363-9.
12. Peng Y, Kang Q, Luo Q, Jiang W, Si W, Liu BA, et al. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem 2004;279:32941-9. (Pubitemid 39014754)
13. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006;38:154-66. (Pubitemid 43165781)
14. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 2005;20:2189-99. (Pubitemid 41698782)
15. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005;65:8274-85. (Pubitemid 41330592)
16. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64:994-9. (Pubitemid 38176902)
17. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 1983;51:918-24. (Pubitemid 13143171)
18. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88:2989-94. (Pubitemid 30413181)
19. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68:74-80.
20. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, et al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 2007;67:3646-53. (Pubitemid 46762149)
21. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005;65:11001-9. (Pubitemid 41713370)
22. Corboz VA, Cecchini MG, Felix R, Fleisch H, van der Pluijm G, Löwik CW. Effect of macrophage colony-stimulating factor on in vitro osteoclast generation and bone resorption. Endocrinology 1992; 130:437-42.